Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jan 1;18(1):84-90.
doi: 10.2215/CJN.0000000000000018.

A Randomized Controlled Trial of Whole-Body Vibration on Gait Ability and Balance among Older Hemodialysis Patients

Yuta Asahina  1 , Yusuke Sakaguchi  2 , Sachio Kajimoto  1 , Koki Hattori  1 , Tatsufumi Oka  1 , Jun-Ya Kaimori  2 , Naoki Kashihara  3 , Yoshitaka Isaka  1
Affiliations
Randomized Controlled Trial

A Randomized Controlled Trial of Whole-Body Vibration on Gait Ability and Balance among Older Hemodialysis Patients

Yuta Asahina et al. Clin J Am Soc Nephrol. .

Abstract

Background: Gait abnormality is a serious problem among hemodialysis patients. Whole-body vibration is a simple exercise that induces sustained muscular contractions through mechanical vibrations. This training improved gait ability in older adults. We aimed to investigate the effect of whole-body vibration on balance and gait ability in older hemodialysis patients.

Methods: We conducted a 12-week, open-label, multicenter, randomized controlled trial of 98 hemodialysis patients, who were aged ≥65 years, from three dialysis centers in Japan. Those who had difficulty walking alone or dementia were excluded. Patients were randomly allocated to the whole-body vibration group or control group. The training was performed for 3 minutes thrice a week on dialysis days. The primary outcome was the Timed Up and Go test. The secondary outcomes were the single-leg stand test and 30-second chair stand test.

Results: The mean (SD) age of the participants was 76 (7) years. The mean (SD) Timed Up and Go test was 12.0 (6.6) and 11.8 (7.0) seconds in the whole-body vibration and control groups, respectively. During the 12-week study period, 6 (12%) of 49 patients in the whole-body vibration group and 3 (6%) of 49 patients in the control group dropped out. In the whole-body vibration group, 42 (86% of the randomly allocated patients) completed the training according to the protocol. The mean (SD) changes in the Timed Up and Go test were -1.1 (4.0) and -1.4 (4.4) seconds in the whole-body vibration and control groups, respectively (change, 0.3 seconds in the whole-body vibration group; 95% confidence interval, -1.4 to 2.0; P=0.71). The changes in the single-leg stand test and 30-second chair stand test did not differ significantly between groups. There were no musculoskeletal adverse events directly related to this training.

Conclusions: Whole-body vibration did not improve balance and gait ability.

Clinical trial registry name and registration number: Effect of Whole Body Vibration on Walking Performance in Elderly Hemodialysis Patients NCT04774731.

PubMed Disclaimer

Conflict of interest statement

Y. Isaka reports research funding from Chugai Pharma Co., Ltd., Kirin Co., Ltd., Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical Co., Ltd.; advisory or leadership roles for Chugai Pharma Co., Ltd. and Kirin Co., Ltd.; and speakers bureau for Astellas Pharma, Inc., AstraZeneca plc, Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical Co., Ltd. N. Kashihara reports consultancy agreements with AstraZeneca, Kyowa Kirin, and Novartis; research funding from Astellas, Daiichi-Sankyo, Otsuka, and Takeda; honoraria from Astellas, Daiichi-Sankyo, Otsuka, and Takeda; advisory or leadership roles for AstraZeneca, Kyowa Kirin, and Novartis; and other interests or relationships with Japan Kidney Association and Japanese Society of Nephrology. Y. Sakaguchi reports research funding from Chugai Pharmaceutical Co., Ltd., FUSO Pharmaceutical Industries, Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Terumo Co., Ltd., and Torii Pharmaceutical Co., Ltd. and honoraria from AstraZeneca, Bayer Yakuhin, Ltd., Chugai Pharmaceutical, Co., Ltd., Fuso, Kyowa Kirin Co., Ltd., and Torii Pharmaceutical, Co., Ltd. The remaining authors have nothing to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
Flow diagram of the study. AV, arteriovenous.
See this image and copyright information in PMC

Comment in

References

    1. Kim JC Shapiro BB Zhang M, et al. . Daily physical activity and physical function in adult maintenance hemodialysis patients. J Cachexia Sarcopenia Muscle. 2014;5(3):209-220. doi:10.1007/s13539-014-0131-4 - DOI - PMC - PubMed
    1. van Loon I Hamaker ME Boereboom FTJ, et al. . A closer look at the trajectory of physical functioning in chronic hemodialysis. Age Ageing. 2017;46(4):594-599. doi:10.1093/ageing/afx006 - DOI - PubMed
    1. Kutner NG, Zhang R, Huang Y, Painter P. Gait speed and mortality, hospitalization, and functional status change among hemodialysis patients: a US Renal Data System special study. Am J Kidney Dis. 2015;66(2):297-304. doi:10.1053/j.ajkd.2015.01.024 - DOI - PMC - PubMed
    1. Kittiskulnam P, Chertow GM, Carrero JJ, Delgado C, Kaysen GA, Johansen KL. Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int. 2017;92(1):238-247. doi:10.1016/j.kint.2017.01.024 - DOI - PMC - PubMed
    1. Erken E Ozelsancak R Sahin S, et al. . The effect of hemodialysis on balance measurements and risk of fall. Int Urol Nephrol. 2016;48(10):1705-1711. doi:10.1007/s11255-016-1388-7 - DOI - PubMed

Publication types

Associated data